[Clinical utility of ulinastatin, urinary protease inhibitor in acute Kawasaki disease].
Ulinastatin, a trypsin inhibitor, is useful as a first-line or a second-line treatment regimen including alternative therapy for IVIG-resistant or IVIG nonresponder Kawasaki disease (KD) patients. Mechanisms involving protections against tissue organs and endthelial cell and anti-inflammatory effects by ulinastatin, are dependent on the inhibition of PMN-derived elastase, tumor necrosis factor alpha (TNFalpha), and other proinflammatory cytokines/interleukins(IL-1, IL-6, IL-8). Ulinastatin also suppresses the activation of PMN cells, macrophages, and platelets. Although almost no statistical data related to the definitive effect in acute stage of KD, ulinastatin have shown possible effects, but not always, in a part of KD patients. The indications of clinical use include shock and pancreatitis. Off-label uses of ulinastatin have been reported in hematological, hepatic, renal, OB/Gy diseases and cardiovascular diseases including vasculitis syndromes. The efficacy of ulinastatin in aKD remained to be investigated.
Saji
Tsutomu
T
Department of Pediatrics, Omori Hospital, Medical Center, Toho University.
D000208:Acute Disease; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D006023:Glycoproteins / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D009080:Mucocutaneous Lymph Node Syndrome / Q000188:drug therapy*; D014361:Trypsin Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*
D006023:Glycoproteins; D014361:Trypsin Inhibitors; C028665:urinastatin